DETERMINE is a cutting edge UK national precision medicine trial in rare cancers, testing a range of therapies specifically targeting key genetic changes in cancer cells.
DETERMINE is an umbrella, basket platform trial evaluating genotype-matched targeted agents outside of their licensed indications in rare adult, TYA and paediatric cancers with actionable genomic alterations.
Current treatment arms
There are currently 7 agents available across 5 arms in the DETERMINE trial, each targeting a specific genomic profile:
1. Alectinib (Alecensa)
2. Atezolizumab (Tecentriq)
3. Entrectinib (Rozlytrek)
4. Trastuzumab (Herceptin) and Pertuzumab (Perjeta)
5. Vemurafenib (Zelboraf) and Cobimetinib (Cotellic)
The trial aims to recruit 800-900 patients, through use of existing, national screening programmes, over the 5-year recruitment period. DETERMINE will be delivered through the Experimental Cancer Medicine Centres (ECMC) Network, which consists of 29 adult and paediatric sites across the UK.
Centre for Drug Development
As the trial sponsor, the Centre for Drug Development (CDD) will be responsible for all aspects of management and delivery of DETERMINE and will act as the central contact point for our partners.
Claire Hyder Business Development Executive, Cancer Research UK
Claire is a Business Development Executive for Clinical Collaborations at Cancer Research Horizons, Cancer Research UK’s commercialisation and innovation engine. Claire works closely with the Cancer Research UK Centre for Drug Development (CDD) and our commercial partners on the early clinical development of novel therapeutic agents.
Our initial collaborator
Our founding commercial partner
We’re proud to be working with Roche. Roche has provided 7 of their targeted therapies to be evaluated in the first instance.